Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 2, 2025

HuH-6

RRID:CVCL_4381
Type: Cell Line

Proper Citation

(RRID:CVCL_4381)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4381

Proper Citation: (RRID:CVCL_4381)

Sex: Male

Defining Citation: PMID:57894, PMID:8389256, PMID:9359923, PMID:9671767, PMID:15767549, PMID:20937217, PMID:22460905, PMID:23505090, PMID:23887712, PMID:30894373, PMID:31063779, PMID:31068700, PMID:31978347, PMID:32899426

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Population: Japanese., Part of: JFCR45 cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: HuH-6

Synonyms: HUH-6, HuH 6, HuH6, HUH6, Huh6

Cross References: BTO:BTO_0001670, CLO:CLO_0050851, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:643, BioSample:SAMN10987713, cancercelllines:CVCL_4381, CCRID:1101HUM-PUMC000477, CCRID:3101HUMTCHu181, Cell_Model_Passport:SIDM00062, CLS:305092, Cosmic:869168, Cosmic:869279, Cosmic:873714, Cosmic:1187329, Cosmic:1237546, Cosmic:1518228, Cosmic:1622750, Cosmic:2162537, Cosmic:2369478, Cosmic:2771602, DepMap:ACH-000671, GEO:GSM887148, GEO:GSM888220, GEO:GSM936762, IARC_TP53:28317,

LiGeA:CCLE_149, Progenetix:CVCL_4381, RCB:RCB1367, Wikidata:Q54896848

ID: CVCL_4381

Record Creation Time: 20250131T200952+0000

Record Last Update: 20250131T202425+0000

Ratings and Alerts

No rating or validation information has been found for HuH-6.

No alerts have been found for HuH-6.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 207 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Song M, et al. (2024) DNA of Neutrophil Extracellular Traps Binds TMCO6 to Impair CD8+ T-cell Immunity in Hepatocellular Carcinoma. Cancer research, 84(10), 1613.

Kong Y, et al. (2023) Lipophagy-mediated cholesterol synthesis inhibition is required for the survival of hepatocellular carcinoma under glutamine deprivation. Redox biology, 63, 102732.

Zhu J, et al. (2023) SNORA14A inhibits hepatoblastoma cell proliferation by regulating SDHB-mediated succinate metabolism. Cell death discovery, 9(1), 36.

Guo T, et al. (2023) Dihydromyricetin functions as a tumor suppressor in hepatoblastoma by regulating SOD1/ROS pathway. Frontiers in oncology, 13, 1160548.

Héraud C, et al. (2023) Identification of an inhibitory domain in GTPase-activating protein p190RhoGAP responsible for masking its functional GAP domain. The Journal of biological chemistry, 299(1), 102792.

Zhou Y, et al. (2023) Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. EBioMedicine, 87, 104397.

Gest C, et al. (2023) Antagonism between wild-type and mutant ?-catenin controls hepatoblastoma differentiation via fascin-1. JHEP reports : innovation in hepatology, 5(5),

100691.

Cui Z, et al. (2023) O-GlcNAcylated LARP1 positively regulated by circCLNS1A facilitates hepatoblastoma progression through DKK4/?-catenin signalling. Clinical and translational medicine, 13(4), e1239.

Tang Y, et al. (2023) ?-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration. Cell communication and signaling : CCS, 21(1), 162.

Eloranta K, et al. (2023) SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration. Frontiers in oncology, 13, 1118268.

Tsuchiya H, et al. (2023) NEAT1-SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines. Current issues in molecular biology, 45(2), 1073.

Nousiainen R, et al. (2023) UBE2C expression is elevated in hepatoblastoma and correlates with inferior patient survival. Frontiers in genetics, 14, 1170940.

Chen DY, et al. (2023) Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. iScience, 26(5), 106634.

Han Y, et al. (2023) BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma. Clinical and translational medicine, 13(5), e1247.

Xie Y, et al. (2023) Anti-ferroptotic PRKAA2 serves as a potential diagnostic and prognostic marker for hepatoblastoma. Journal of gastrointestinal oncology, 14(4), 1788.

Liu L, et al. (2022) The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clinical and translational medicine, 12(5), e778.

Sakaguchi H, et al. (2022) NEAT1 Confers Radioresistance to Hepatocellular Carcinoma Cells by Inducing Autophagy through GABARAP. International journal of molecular sciences, 23(2).

Wang D, et al. (2022) Mitochondrial fragmentation is crucial for c-Myc-driven hepatoblastoma-like liver tumors. Molecular therapy : the journal of the American Society of Gene Therapy, 30(4), 1645.

Huge N, et al. (2022) MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF. Cancer cell international, 22(1), 192.

Li Q, et al. (2022) Targeting the Unwindosome by Mebendazole Is a Vulnerability of Chemoresistant Hepatoblastoma. Cancers, 14(17).